Breast Cancer Diagnostics Market

Breast Cancer Diagnostics Market By Types (Imaging, Biopsy, Genomic Tests, and Blood Tests), Products (Platform-based [Next-generation Sequencing, Microarrays, PCR, and Others] and Instrument-based [Imaging and Biopsy]), Applications (Screening, Diagnostic & Predictive, Prognostic, and Research), End-users (Hospitals & Clinics, Diagnostic Centers & Medical Laboratories, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021–2028

  • Report ID: HC-791
  • Author: Growth Market Reports
  • Rating: 4.9
  • Total Reviews: 2
  • No. Of Pages: 175
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global breast cancer diagnostics market size was valued at USD 3.92 billion in 2020 and is projected to expand at a CAGR of 6.7% during the forecast period, 2021 – 2028. The growth of the market is attributed to rising government efforts to raise cancer screening and diagnosis rates as well as the rising incidence of cancer.

Breast cancer occurs due to the disorderly expansion of the cells and tissues of the breast and appears as a lump surrounding the internal breast tissues, usually developing into a tumor. Breast cancer is a malignant tumor that almost exclusively affects women, with a few exceptions in adults. Breast cancer is now the most prevalent cancer in women all around the world. The number of women diagnosed with breast cancer is on the rise. Therefore, it becomes necessary for the early detection of the breast cancer among women. Early detection of cancer increases the chances of preventing the progress of the cancer and increase the chance of survival of patients significantly. Breast cancer can be detected early due to raising awareness as well as encouraging early diagnosis and screening.

Global Breast Cancer Diagnostics Market Summary

Market Trends, Drivers, Restraints, and Opportunities:

  • Increasing number of private diagnostic centers and development of innovative diagnostic imaging procedures are expected to boost the market expansion.
  • Rising establishment of public hospitals and centers specialized for the treatment of cancer across the globe present key driving factors for the market.
  • Growing demand for technologically advanced products that can improve accuracy, speed, and cost-effectiveness for cancer detection is propelling the market growth.
  • Governments sponsored awareness activities and initiatives in developed countries encouraging and guiding primary care doctors to recommend cancer screening tests for patients are propelling the market expansion.
  • Higher cost of diagnostics and lack of effective reimbursement rates, and budgetary restrictions among patients from developing countries are key challenges that can hamper the market growth.

Scope of the Report

The report on the global breast cancer diagnostics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Breast Cancer Diagnostics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Types (Imaging, Biopsy, Genomic Tests, and Blood Tests), Products (Platform-based [Next-generation Sequencing, Microarrays, PCR, and Others] and Instrument-based [Imaging and Biopsy]), Applications (Screening, Diagnostic & Predictive, Prognostic, and Research), End-users (Hospitals & Clinics, Diagnostic Centers & Medical Laboratories, and Others),

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Hologic Inc.; Genomic Health (Exact Sciences Corporation); BD; Danaher; Koninklijke Philips N.V.; QIAGEN; Thermo Fisher Scientific Inc.; Myriad Genetics; Argon Medical Devices, Inc.; F. Hoffmann-La Roche Ltd.

 

Breast Cancer Diagnostics Market Segment Insights

Imaging segment is expected to dominate the market
Based on types, the global breast cancer diagnostics market is segmented into imaging, biopsy, genomic tests, and blood tests. The Imaging segment held a dominant market share, representing over 70.3% in 2020 and is expected to continue the trend in the coming years. The segment growth is attributed to factors such as large volume of procedures, easy accessibility, and enhanced effectiveness of imagining technology. Mammograms, ultrasound, and magnetic resonance imaging (MRI) are some of the most common imaging techniques used for screening and diagnosis. Furthermore, a number of advanced new imaging techniques for breast cancer diagnosis such as breast tomosynthesis, Molecular Breast Imaging (MBI), CT, and PET, are poised to change the landscape of breast imaging segment.

On the other hand, the blood test segment is expected to grow significantly during the forecast period due to growing research studies carried out by the research organizations and major players to ensure high efficacy of liquid biopsy tests.

Global Breast Cancer Diagnostics Market By Type

Instrument-based testing segment to hold a key share market
On the basis of products, the market is bifurcated into platform-based and instrument-based. The platform-based segment is further segmented into next-generation sequencing, microarrays, PCR, and others. The instrument-based segment is also further segmented into imaging and biopsy. The instrument-based testing segment is expected to dominate the market, accounting for more than 70.2% in 2020. The segment growth is due to wide adoption of imaging devices as the first choice for general population-based screening of breast cancer patients. All patients with breast cancer undergo a biopsy to confirm their diagnosis. Many organizations, such as the National Breast Cancer Foundation, Inc., are working to raise awareness about breast cancer, the importance of early detection, and treatment options.

On the other hand, the platform-based products segment is anticipated to expand at a rapid pace during the forecast period due to innovation of the products and the higher preference of such products for targeted therapy.

Global Breast Cancer Diagnostics Market By Product

Diagnostics & predictive segment to constitute a large share
Based on applications, the global breast cancer diagnostics market is segmented into screening, diagnostic & predictive, prognostic, and research. The diagnostics & predictive segment is anticipated to constitute a dominant market share representing with an impressive CAGR during the forecast period due to the increasing prevalence of genetic testing. Meanwhile, the prognostic segment is anticipated to expand at a significant growth rate during the forecast period as these tests are used to match patients with therapies, they are becoming more important.

Hospitals & clinics segment to register a robust CAGR
On the basis of end-users, the market is segmented into hospitals & clinics, diagnostic centers & medical laboratories, and others. The hospitals & clinics segment is expected to register a robust CAGR during the forecast period owing to increasing hospitalization of patients and the growing load of the disease. Patients usually prefer to undergo biopsy for confirmatory testing in hospitals after the screening test. Additionally, PET, CT, and MRI are used to track disease progression and determine the efficacy of cancer treatments.

Diagnostic centers & medical laboratories segment, however, is anticipated to grow significantly during the forecast period due to a rise in the number of government initiatives to provide different services, such as diagnostic test reimbursement.

North America is likely to dominate the market
In terms of regions, the global breast cancer diagnostics market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is likely to dominate the market due to factors such as the presence of major players, well-established diagnostic and screening infrastructure, technological advances, high patient knowledge, and favorable reimbursement policies. Meanwhile, the market in Asia Pacific segment is expected to grow at a rapid pace during the forecast period. The regional market growth is due to the incidence of breast cancer and the adoption of advanced diagnostic techniques among the patients in the region. Furthermore, growing easy policy of reimbursement guidelines and expanding healthcare infrastructure from governments present key factors pushing the market expansion.

Global Breast Cancer Diagnostics Market By Region

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Breast Cancer Diagnostics Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Breast Cancer Diagnostics Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Breast Cancer Diagnostics Market - Supply Chain
  4.5. Global Breast Cancer Diagnostics Market Forecast
     4.5.1. Breast Cancer Diagnostics Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Breast Cancer Diagnostics Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Breast Cancer Diagnostics Market Absolute $ Opportunity
5. Global Breast Cancer Diagnostics Market Analysis and Forecast by Types
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Types
     5.2.2. Y-o-Y Growth Projections by Types
  5.3. Breast Cancer Diagnostics Market Size and Volume Forecast by Types
     5.3.1. Imaging
     5.3.2. Biopsy
     5.3.3. Genomic Tests
     5.3.4. Blood Tests
     5.3.5. Others
  5.4. Absolute $ Opportunity Assessment by Types
  5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Breast Cancer Diagnostics Market Analysis and Forecast by Applications
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by Applications
     6.2.2. Y-o-Y Growth Projections by Applications
  6.3. Breast Cancer Diagnostics Market Size and Volume Forecast by Applications
     6.3.1. Screening
     6.3.2. Diagnostic & Predictive
     6.3.3. Prognostic
     6.3.4. Research
  6.4. Absolute $ Opportunity Assessment by Applications
  6.5. Market Attractiveness/Growth Potential Analysis by Applications
7. Global Breast Cancer Diagnostics Market Analysis and Forecast by End Users
  7.1. Market Trends
  7.2. Introduction
     7.2.1. Basis Point Share (BPS) Analysis by End Users
     7.2.2. Y-o-Y Growth Projections by End Users
  7.3. Breast Cancer Diagnostics Market Size and Volume Forecast by End Users
     7.3.1. Hospitals & Clinics
     7.3.2. Diagnostic Centers & Medical Laboratories
     7.3.3. Others
  7.4. Absolute $ Opportunity Assessment by End Users
  7.5. Market Attractiveness/Growth Potential Analysis by End Users
8. Global Breast Cancer Diagnostics Market Analysis and Forecast by Region
  8.1. Market Trends
  8.2. Introduction
     8.2.1. Basis Point Share (BPS) Analysis by Region
     8.2.2. Y-o-Y Growth Projections by Region
  8.3. Breast Cancer Diagnostics Market Size and Volume Forecast by Region
     8.3.1. North America
     8.3.2. Latin America
     8.3.3. Europe
     8.3.4. Asia Pacific
     8.3.5. Middle East and Africa (MEA)
  8.4. Absolute $ Opportunity Assessment by Region
  8.5. Market Attractiveness/Growth Potential Analysis by Region
  8.6. Global Breast Cancer Diagnostics Demand Share Forecast, 2019-2026
9. North America Breast Cancer Diagnostics Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
  9.2. North America Breast Cancer Diagnostics Market Size and Volume Forecast by Country
     9.2.1. U.S.
     9.2.2. Canada
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. North America Breast Cancer Diagnostics Market Size and Volume Forecast by Types
     9.4.1. Imaging
     9.4.2. Biopsy
     9.4.3. Genomic Tests
     9.4.4. Blood Tests
     9.4.5. Others
  9.5. Basis Point Share (BPS) Analysis by Types
  9.6. Y-o-Y Growth Projections by Types
  9.7. North America Breast Cancer Diagnostics Market Size and Volume Forecast by Applications
     9.7.1. Screening
     9.7.2. Diagnostic & Predictive
     9.7.3. Prognostic
     9.7.4. Research
  9.8. Basis Point Share (BPS) Analysis by Applications
  9.9. Y-o-Y Growth Projections by Applications
  9.10. North America Breast Cancer Diagnostics Market Size and Volume Forecast by End Users
     9.10.1. Hospitals & Clinics
     9.10.2. Diagnostic Centers & Medical Laboratories
     9.10.3. Others
  9.11. Basis Point Share (BPS) Analysis by End Users
  9.12. Y-o-Y Growth Projections by End Users
  9.13. Market Attractiveness/Growth Potential Analysis
     9.13.1. By Country
     9.13.2. By Product Type
     9.13.3. By Application
  9.14. North America Breast Cancer Diagnostics Demand Share Forecast, 2019-2026
10. Latin America Breast Cancer Diagnostics Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Latin America Average Pricing Analysis
  10.2. Latin America Breast Cancer Diagnostics Market Size and Volume Forecast by Country
      10.2.1. Brazil
      10.2.2. Mexico
      10.2.3. Rest of Latin America
   10.3. Absolute $ Opportunity Assessment by Country
  10.4. Latin America Breast Cancer Diagnostics Market Size and Volume Forecast by Types
     10.4.1. Imaging
     10.4.2. Biopsy
     10.4.3. Genomic Tests
     10.4.4. Blood Tests
     10.4.5. Others
  10.5. Basis Point Share (BPS) Analysis by Types
  10.6. Y-o-Y Growth Projections by Types
  10.7. Latin America Breast Cancer Diagnostics Market Size and Volume Forecast by Applications
     10.7.1. Screening
     10.7.2. Diagnostic & Predictive
     10.7.3. Prognostic
     10.7.4. Research
  10.8. Basis Point Share (BPS) Analysis by Applications
  10.9. Y-o-Y Growth Projections by Applications
  10.10. Latin America Breast Cancer Diagnostics Market Size and Volume Forecast by End Users
     10.10.1. Hospitals & Clinics
     10.10.2. Diagnostic Centers & Medical Laboratories
     10.10.3. Others
  10.11. Basis Point Share (BPS) Analysis by End Users
  10.12. Y-o-Y Growth Projections by End Users
  10.13. Market Attractiveness/Growth Potential Analysis
     10.13.1. By Country
     10.13.2. By Product Type
     10.13.3. By Application
  10.14. Latin America Breast Cancer Diagnostics Demand Share Forecast, 2019-2026
11. Europe Breast Cancer Diagnostics Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Europe Average Pricing Analysis
  11.2. Europe Breast Cancer Diagnostics Market Size and Volume Forecast by Country
     11.2.1. Germany
     11.2.2. France
     11.2.3. Italy
     11.2.4. U.K.
     11.2.5. Spain
     11.2.6. Russia
     11.2.7. Rest of Europe
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Europe Breast Cancer Diagnostics Market Size and Volume Forecast by Types
     11.4.1. Imaging
     11.4.2. Biopsy
     11.4.3. Genomic Tests
     11.4.4. Blood Tests
     11.4.5. Others
  11.5. Basis Point Share (BPS) Analysis by Types
  11.6. Y-o-Y Growth Projections by Types
  11.7. Europe Breast Cancer Diagnostics Market Size and Volume Forecast by Applications
     11.7.1. Screening
     11.7.2. Diagnostic & Predictive
     11.7.3. Prognostic
     11.7.4. Research
  11.8. Basis Point Share (BPS) Analysis by Applications
  11.9. Y-o-Y Growth Projections by Applications
  11.10. Europe Breast Cancer Diagnostics Market Size and Volume Forecast by End Users
     11.10.1. Hospitals & Clinics
     11.10.2. Diagnostic Centers & Medical Laboratories
     11.10.3. Others
  11.11. Basis Point Share (BPS) Analysis by End Users
  11.12. Y-o-Y Growth Projections by End Users
  11.13. Market Attractiveness/Growth Potential Analysis
     11.13.1. By Country
     11.13.2. By Product Type
     11.13.3. By Application
  11.14. Europe Breast Cancer Diagnostics Demand Share Forecast, 2019-2026
12. Asia Pacific Breast Cancer Diagnostics Market Analysis and Forecast
  12.1. Introduction
     12.1.1. Basis Point Share (BPS) Analysis by Country
     12.1.2. Y-o-Y Growth Projections by Country
     12.1.3. Asia Pacific Average Pricing Analysis
  12.2. Asia Pacific Breast Cancer Diagnostics Market Size and Volume Forecast by Country
     12.2.1. China
     12.2.2. Japan
     12.2.3. South Korea
     12.2.4. India
     12.2.5. Australia
     12.2.6. Rest of Asia Pacific (APAC)
  12.3. Absolute $ Opportunity Assessment by Country
  12.4. Asia Pacific Breast Cancer Diagnostics Market Size and Volume Forecast by Types
     12.4.1. Imaging
     12.4.2. Biopsy
     12.4.3. Genomic Tests
     12.4.4. Blood Tests
     12.4.5. Others
  12.5. Basis Point Share (BPS) Analysis by Types
  12.6. Y-o-Y Growth Projections by Types
  12.7. Asia Pacific Breast Cancer Diagnostics Market Size and Volume Forecast by Applications
     12.7.1. Screening
     12.7.2. Diagnostic & Predictive
     12.7.3. Prognostic
     12.7.4. Research
  12.8. Basis Point Share (BPS) Analysis by Applications
  12.9. Y-o-Y Growth Projections by Applications
  12.10. Asia Pacific Breast Cancer Diagnostics Market Size and Volume Forecast by End Users
     12.10.1. Hospitals & Clinics
     12.10.2. Diagnostic Centers & Medical Laboratories
     12.10.3. Others
  12.11. Basis Point Share (BPS) Analysis by End Users
  12.12. Y-o-Y Growth Projections by End Users
  12.13. Market Attractiveness/Growth Potential Analysis
     12.13.1. By Country
     12.13.2. By Product Type
     12.13.3. By Application
  12.14. Asia Pacific Breast Cancer Diagnostics Demand Share Forecast, 2019-2026
13. Middle East & Africa Breast Cancer Diagnostics Market Analysis and Forecast
  13.1. Introduction
     13.1.1. Basis Point Share (BPS) Analysis by Country
     13.1.2. Y-o-Y Growth Projections by Country
     13.1.3. Middle East & Africa Average Pricing Analysis
  13.2. Middle East & Africa Breast Cancer Diagnostics Market Size and Volume Forecast by Country
     13.2.1. Saudi Arabia
     13.2.2. South Africa
     13.2.3. UAE
     13.2.4. Rest of Middle East & Africa (MEA)
  13.3. Absolute $ Opportunity Assessment by Country
  13.4. Middle East & Africa Breast Cancer Diagnostics Market Size and Volume Forecast by Types
     13.4.1. Imaging
     13.4.2. Biopsy
     13.4.3. Genomic Tests
     13.4.4. Blood Tests
     13.4.5. Others
  13.5. Basis Point Share (BPS) Analysis by Types
  13.6. Y-o-Y Growth Projections by Types
  13.7. Middle East & Africa Breast Cancer Diagnostics Market Size and Volume Forecast by Applications
     13.7.1. Screening
     13.7.2. Diagnostic & Predictive
     13.7.3. Prognostic
     13.7.4. Research
  13.8. Basis Point Share (BPS) Analysis by Applications
  13.9. Y-o-Y Growth Projections by Applications
  13.10. Middle East & Africa Breast Cancer Diagnostics Market Size and Volume Forecast by End Users
     13.10.1. Hospitals & Clinics
     13.10.2. Diagnostic Centers & Medical Laboratories
     13.10.3. Others
  13.11. Basis Point Share (BPS) Analysis by End Users
  13.12. Y-o-Y Growth Projections by End Users
  13.13. Market Attractiveness/Growth Potential Analysis
     13.13.1. By Country
     13.13.2. By Product Type
     13.13.3. By Application
  13.14. Middle East & Africa Breast Cancer Diagnostics Demand Share Forecast, 2019-2026
14. Competition Landscape
  14.1. Global Breast Cancer Diagnostics Market: Market Share Analysis
  14.2. Breast Cancer Diagnostics Distributors and Customers
  14.3. Breast Cancer Diagnostics Market: Competitive Dashboard
  14.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     14.4.1. Hologic Inc.
     14.4.2. Genomic Health (Exact Sciences Corporation)
     14.4.3. BD
     14.4.4. Danaher
     14.4.5. Koninklijke Philips N.V.
     14.4.6. QIAGEN
     14.4.7. Thermo Fisher Scientific Inc.
     14.4.8. Myriad Genetics
Segments Covered in the Report
The global breast cancer diagnostics market has been segmented on the basis of

Types
  • Imaging
  • Biopsy
  • Genomic Tests
  • Blood Tests
  • Others
Products
  • Platform-based Products
    • Next-generation Sequencing
    • Microarrays
    • PCR
    • Others
  • Instrument-based Products
    • Imaging
    • Biopsy
Applications
  • Screening
  • Diagnostic & Predictive
  • Prognostic
  • Research
End-users
  • Hospitals & Clinics
  • Diagnostic Centers & Medical Laboratories
  • Others
Regions
  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa
Key Players
  • Hologic Inc.
  • Genomic Health (Exact Sciences Corporation)
  • BD
  • Danaher
  • Koninklijke Philips N.V.
  • QIAGEN
  • Thermo Fisher Scientific Inc.
  • Myriad Genetics
  • Argon Medical Devices, Inc.
  • F. Hoffmann-La Roche Ltd.

Some of the major companies competing in the market are Hologic Inc.; Genomic Health (Exact Sciences Corporation); BD; Danaher; Koninklijke Philips N.V.; QIAGEN; Thermo Fisher Scientific Inc.; Myriad Genetics; Argon Medical Devices, Inc.; F. Hoffmann-La Roche Ltd.

Several market strategies such as mergers, acquisitions, and alliances are being used by major corporations to increase their global market share. Hologic Inc. acquired Biotheranostics and SOMATEX Medical Technologies GmbH in January 2021. Thermo Fisher Scientific, Inc. negotiated a partnership with AstraZeneca and the University of Nebraska Medical Center in September 2020 to develop innovative clinical biomarkers. In addition, the firm signed an agreement with Pfizer, Inc. in October 2018 to use BRACAnalysis CDx as a companion diagnostic with Pfizer's patented talazoparib.

Global Breast Cancer Diagnostics Market By Key Players

Buy Report